InDex Pharmaceuticals Holding AB (publ) interim report January – March 2022
Full focus on the phase III study CONCLUDE with cobitolimod
Press releases
InDex Pharmaceuticals strengthens the organization with Eva Arlander as Chief Development Officer and announces changes in the composition of the management team
May 2, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has appointed Eva Arlander as Chief Development Officer. Eva will also be part of the management team, together with acting Chief Executive Officer and Chief Financial Officer Johan Giléus, Chief Medical Officer Anders Bröijersén and Chief Scientific Officer Charlotte Admyre.
Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
28 April 2022 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820 (the “Company”), are hereby summoned to the Annual General Meeting on Wednesday 1 June, 2022 at 17.00 (CET) through advance voting. Attendance at the meeting is only possible via postal ballot.
Peter Zerhouni steps down as CEO of InDex Pharmaceuticals
April 11, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that after more than seven years as CEO, Peter Zerhouni has decided to leave his position. The company’s CFO Johan Giléus has been appointed acting CEO while a new CEO is being recruited, and he will also continue as CFO.
InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2021
April 8, 2022 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2021. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports/.
InDex Pharmaceuticals prepares for commercialisation of cobitolimod
March 13, 2022 – InDex Pharmaceuticals Holding AB (publ) is planning for self-commercialisation of the drug candidate cobitolimod in the US with strategic collaborations in other regions. Launch is expected in 2027, with the potential for annual sales to reach more than USD 1 billion, in moderate to severe left-sided ulcerative colitis. An in-depth presentation of the strategy and market potential, together with the execution of the phase III study CONCLUDE with cobitolimod will be provided at InDex’s Capital Markets Day, tomorrow March 14, 15.00-17.00 CET.
InDex Pharmaceuticals Holding AB (publ) year-end report 2021
First patient enrolled in the phase III study CONCLUDE
COO Pernilla Sandwall is leaving InDex Pharmaceuticals for a CEO position
February 13, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that Chief Operating Officer Pernilla Sandwall has decided to leave the company to become CEO of WntResearch. She will continue in her current role until the end of April. The process to recruit her successor will be initiated immediately.
InDex Pharmaceuticals enrols first patient in the phase III study CONCLUDE with cobitolimod in ulcerative colitis
November 24, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the pivotal phase III study CONCLUDE. The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod as a novel treatment for patients with moderate to severe left-sided ulcerative colitis.
InDex Pharmaceuticals Holding AB (publ) interim report January – September 2021
Ready to initiate patient recruitment in phase III study CONCLUDE
InDex Pharmaceuticals gets new patent for cobitolimod granted in Canada
November 16, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Canadian Intellectual Property Office (CIPO). The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
InDex Pharmaceuticals gets new patent for cobitolimod granted in the US
November 9, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the United States Patent and Trademark Office (USPTO). The patent provides protection for the use of certain dosage regimens of cobitolimod for treating inflammatory bowel disease, including the 250 mg dose which was successful in the phase IIb study CONDUCT.
InDex Pharmaceuticals Holding AB (publ) interim report January – June 2021
First regulatory approvals to start the phase III study CONCLUDE
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
August 24, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has given clearance to start the phase III clinical study CONCLUDE in the United States. The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.
InDex Pharmaceuticals receives first regulatory approval to start the phase III study CONCLUDE with cobitolimod
July 21, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the Swedish Medical Products Agency (MPA) has given approval to start the phase III clinical study CONCLUDE in Sweden. The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.
Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
June 3, 2021 – The annual general meeting in InDex Pharmaceuticals Holding AB (publ) was held on Thursday June 3, 2021. The following resolutions, amongst others, were passed at the general meeting:
InDex Pharmaceuticals will initiate patient recruitment for the Phase III study CONCLUDE after the summer
May 31, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that patient recruitment for the phase III study CONCLUDE is planned to initiate after the summer. The study will evaluate the efficacy and safety of the drug candidate cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.
InDex Pharmaceuticals Holding AB (publ) interim report January – March 2021
The crucial pieces of the puzzle in place for the start of phase III
Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
May 4, 2021 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820 (the “Company”), are hereby summoned to the Annual General Meeting on Thursday 3 June, 2021 at 17.00 (CET) through advance voting. Attendance at the meeting is only possible via postal ballot.
InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2020
April 23, 2021 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2020. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports-and-presentations/.
InDex Pharmaceuticals Holding AB (publ) year-end report 2020
Financing secured for phase III development of cobitolimod
InDex Pharmaceuticals’ rights issue is oversubscribed
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.
9 February 2021 – The subscription period of the rights issue in InDex Pharmaceuticals Holding AB (publ) (”InDex” or the “Company”) ended on 5 February 2021. The subscription ratio in the rights issue amounted to 152.6 percent. Guarantee commitments made in connection with the rights issue will thus not be utilized. InDex will, through the rights issue, receive approximately SEK 533 million before deduction of costs related to the transaction.
InDex Pharmaceuticals Holding AB publishes prospectus in connection with a fully guaranteed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.
21 January 2021 – The board of directors of InDex Pharmaceuticals Holding AB (publ) (”InDex” or the “Company”) has prepared a prospectus in connection with the rights issue of approximately MSEK 533 announced through a press release on 14 January 2021 (the “Rights Issue”). The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company’s website.
The board of directors of InDex Pharmaceuticals Holding AB has resolved on a fully guaranteed rights issue of approximately MSEK 533
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.
14 January 2021 – The board of directors of InDex Pharmaceuticals Holding AB (publ) (”InDex” or the ”Company”) has, with the support of the authorisation from the extraordinary general meeting held on 12 January 2021, resolved on a rights issue of approximately 444 million shares at a subscription price of SEK 1.20 per share (the “Rights Issue”). The Rights Issue is fully covered by subscription undertakings and guarantee commitments from existing shareholders and new investors, including amongst others HBM Healthcare Investments, Handelsbanken Funds, Linc and The Fourth Swedish National Pension Fund. At full subscription in the Rights Issue the Company will receive approximately MSEK 533 before deduction of costs related to the transaction.
Bulletin from the Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)
12 January 2021 – The Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) was held on 12 January 2021 at the offices of Setterwalls Advokatbyrå at Sturegatan 10, Stockholm. Attendance at the meeting was solely possible via postal voting. The following resolutions were passed at the general meeting.
Notice of Extraordinary General Meeting in InDex Pharmaceuticals Holding AB
December 9, 2020 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to an Extraordinary General Meeting on Tuesday 12 January, 2021 at 10.00 p.m. (CET) through advance voting. Attendance at the meeting is only possible via postal ballot.
InDex Pharmaceuticals Holding AB (publ) interim report January – September 2020
Phase III plan laid out
InDex Pharmaceuticals intends to carry out a fully guaranteed rights issue of approximately SEK 500 million to fund phase III development of cobitolimod
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.
November 25, 2020 – InDex Pharmaceuticals Holding AB (publ) (“InDex” or the “Company”) (Nasdaq First North Growth Market: INDEX) intends to carry out a fully guaranteed rights issue of approximately SEK 500 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The Company’s Board of Directors intends to propose that an extraordinary general meeting to be held in January 2021 (the “EGM”) would authorize the Board of Directors to resolve on the Rights Issue and the terms thereof. The net proceeds from the contemplated Rights Issue are mainly intended to be used to fund the important initial induction study in a sequential phase III program in moderate to severe left-sided ulcerative colitis for the Company’s lead drug candidate, cobitolimod. A notice to the EGM will be announced through a separate press release at a later date.
InDex Pharmaceuticals Holding AB (publ) interim report January – June 2020
Focus on phase III preparations
InDex Pharmaceuticals Holding AB (publ) interim report January – March 2020
FDA and EMA endorse the advancement of cobitolimod into phase III studies
Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
April 20, 2020 – The annual general meeting in InDex Pharmaceuticals Holding AB (publ) was held on Monday 20 April 2020 at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm, Sweden. The following resolutions, amongst others, were passed at the general meeting:
InDex Pharmaceuticals advances cobitolimod further towards phase III following successful interactions with FDA and EMA
April 16, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has received positive responses from FDA and EMA regarding phase III development of the company’s TLR9 agonist cobitolimod, for the treatment of moderate to severe ulcerative colitis. The company is continuing its phase III preparations, including efforts to secure financing.
InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2019
March 30, 2020 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2019. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/category/annual-reports/.
Notice to attend the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting. In case of any discrepancies between the Swedish and English language versions, the Swedish version shall prevail.
March 19, 2020 – The shareholders in InDex Pharmaceuticals Holding AB, reg. no. 559067-6820 (the “Company”), are hereby given notice to attend the annual general meeting at 5 p.m. on Monday 20 April 2020 at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm. Registration for the meeting commences at 4.30 p.m.
InDex Pharmaceuticals Holding AB (publ) year-end report 2019
Cobitolimod’s outstanding combination of efficacy and safety confirmed in in-depth analysis
InDex Pharmaceuticals’ in-depth analysis of the CONDUCT study confirms the successful top line results and supports the strategy going forward
February 19, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced the conclusions from in-depth analysis of the complete data set from the phase IIb dose optimisation study CONDUCT, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The analysis confirms that the highest dose tested, which met the primary endpoint of the study, demonstrates an outstanding combination of efficacy and safety.
InDex Pharmaceuticals Holding AB (publ) interim report January – September 2019
Outstanding combination of efficacy and safety in the CONDUCT study
Bulletin from Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)
October 9, 2019 – An Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) (“InDex” or the “Company”) took place on Wednesday, October 9, 2019 in the Company´s premises at Tomtebodavägen 23a in Stockholm, Sweden. At the Extraordinary General Meeting the following was resolved.
Notice of Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)
September 19, 2019 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to an Extraordinary General Meeting on Wednesday October 9, 2019 at 4:00 p.m. (CET) at the Company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 3:30 p.m.
InDex Pharmaceuticals has completed a directed share issue of approximately SEK 140 million (USD 14 million)
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA, THE “UNITED STATES”), AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
September 19, 2019 – The Board of Directors of InDex Pharmaceuticals Holding AB (“InDex” or the “Company”) (Nasdaq First North Growth Market: INDEX) has, as communicated in the Company’s press release earlier today, resolved to issue a maximum of 20,000,000 shares (the “New Shares”), where a maximum of 13,756,255 shares are issued based on the authorization granted by InDex’s annual general meeting on 6 May 2019 and a maximum of 6,243,745 shares are issued subject to the subsequent approval of the extraordinary general meeting (together “Directed Share Issue”). The subscription price in the Directed Share Issue is SEK 6.98 per share and corresponds to the closing price on Nasdaq First North Growth Market on 19 September 2019. The subscription price in the Directed Share Issue has been determined through an accelerated book building procedure (the “Book building”). Through the Directed Share Issue, InDex will receive proceeds amounting to approximately SEK 140 million before transaction related costs. Investors in the Directed Share Issue are a wide range of Swedish and international investors including reputable new investors such as the Fourth Swedish National Pension Fund as well as current shareholders such as Stiftelsen Industrifonden and Bengt Julander (through Linc AB).
InDex Pharmaceuticals announces intention of a directed share issue
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA, THE “UNITED STATES”), AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
September 19, 2019 – InDex Pharmaceuticals Holding AB (publ) (“InDex” or the “Company”) (Nasdaq First North Growth Market: INDEX) hereby announces its intention of a placement of shares corresponding to up to approximately 30 percent of the total number of shares in the Company through issuance of new shares directed to Swedish and international institutional investors. The directed share issue is intended to be carried out, in part based on the authorization granted by the annual general meeting held on 6 May, 2019, and in part subject to the approval of an extraordinary general meeting (together the “Directed Share Issue”). InDex has engaged Carnegie Investment Bank AB (publ) and Pareto Securities AB to act as Joint Bookrunners (together the “Joint Bookrunners”) in connection with the Directed Share Issue.
InDex Pharmaceuticals updates shareholders list
September 5, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders has been updated on the homepage with information as of August 30, 2019.
InDex Pharmaceuticals meets primary endpoint in the phase IIb study CONDUCT with cobitolimod in ulcerative colitis
· Outstanding combination of efficacy and safety
· 15% delta vs. placebo for clinical remission
August 27, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced positive top line results from the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint of clinical remission, demonstrating a superior efficacy of 15% (delta) in patients receiving the highest dose of cobitolimod compared to placebo. Cobitolimod was well tolerated at all dose levels and no differences in the safety profile were observed compared to placebo.
InDex Pharmaceuticals Holding AB (publ) interim report January – June 2019
Last patient enrolled in the CONDUCT study
InDex Pharmaceuticals gets new patent in Europe
June 26, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
InDex Pharmaceuticals enrolls last patient in phase IIb study CONDUCT with cobitolimod
June 26, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that patient enrolment was completed in the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of moderate to severe ulcerative colitis. Top line results are expected to be available in 8-10 weeks.
Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
May 6, 2019 – The Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) took place on Monday, May 6, 2019 in the company´s premises at Tomtebodavägen 23a in Stockholm, Sweden.
InDex Pharmaceuticals Holding AB (publ) interim report January – March 2019
The final phase of the patient recruitment in the CONDUCT study
InDex Pharmaceuticals provides status update on the patient recruitment in the CONDUCT study
April 11, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that 197 patients, of the total 215 planned, have been enrolled to date in the CONDUCT study evaluating the drug candidate cobitolimod. The patient recruitment has varied significantly on a monthly basis, with between 6 and 19 patients enrolled, which makes it challenging to predict the remaining recruitment time. The company estimates that the patient recruitment will be completed during the month of June at the latest, which represents a delay compared to the previously communicated timeline. The company will announce when the last patient has been enrolled in the study and the top line results are expected to be available within 8-10 weeks thereafter.
Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
April 5, 2019 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on Monday May 6, 2019 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.
InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2018
April 2, 2019 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2018, which is earlier than indicated in the financial calendar. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, http://www.indexpharma.com.
InDex Pharmaceuticals Holding AB (publ) year end report 2018
Continued focus on the patient recruitment for the CONDUCT study
InDex Pharmaceuticals Holding AB (publ) interim report January – September 2018
Directed share issue strengthens the cash position ahead of the CONDUCT results
InDex Pharmaceuticals carries out a directed share issue of approximately SEK 37.5 million
October 23, 2018 – The board of directors of InDex Pharmaceuticals Holding AB (publ) (the “Company” or “InDex”) has, with support from the authorization granted by the annual general meeting on May 24, 2018, resolved on a directed share issue of 6,252,842 shares to a small group of investors. The subscription price is SEK 6.02 per share, corresponding to a discount in line with market conditions of 7.7 percent to the 5-day volume weighted average price and 1.3 percent to today’s closing price. InDex will receive proceeds of approximately SEK 37.5 million after transaction related costs for legal services and costs for registration and practical management.
InDex Pharmaceuticals Holding AB (publ) interim report January – June 2018
Updated timeline for the top line results from the CONDUCT study
InDex Pharmaceuticals updates timeline for top line results from the CONDUCT study to first half of 2019
August 9, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced an updated timeline for patient recruitment in the ongoing phase IIb study CONDUCT with the drug candidate cobitolimod. Top line results from the study are now expected in the first half of 2019 instead of in the fourth quarter of 2018 as previously communicated.
Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
May 24, 2018 – The Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) took place on Thursday, May 24, 2018 in the company´s premises at Tomtebodavägen 23a in Stockholm, Sweden.
InDex Pharmaceuticals Holding AB (publ) interim report January – March 2018
Novel formulation for oral administration of cobitolimod
InDex Pharmaceuticals develops oral formulation of cobitolimod
May 4, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that it has developed a novel formulation of its lead drug candidate cobitolimod for oral administration, with targeted delivery to the lower part of the gastrointestinal tract. The oral formulation of cobitolimod is a potential follow-on product to the topical formulation, which is currently being investigated in the CONDUCT study – a phase IIb dose optimisation study in moderate to severe active ulcerative colitis.
InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2017
April 24, 2018 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2017. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, http://www.indexpharma.com.
Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
April 23, 2018 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on May 24, 2018 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.
InDex Pharmaceuticals gets new patent in Japan
Mars 28, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the Japan Patent Office. The patent provides additional protection for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy, wherein cobitolimod is not administered in combination with corticosteroid or glucocorticosteroid.
InDex Pharmaceuticals Holding AB (publ) year end report 2017
Deepened understanding of cobitolimod’s mechanism of action
InDex Pharmaceuticals reports new mechanism of action data for cobitolimod
December 1, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced new scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate. The findings show that cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response.
InDex Pharmaceuticals Holding AB (publ) interim report January – September 2017
Strengthened patent protection for cobitolimod
InDex Pharmaceuticals gets new patent in the US
October 12, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy, wherein cobitolimod is not administered in combination with corticosteroid or glucocorticosteroid.
InDex Pharmaceuticals gets new patent granted in Japan
September 13, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Japan Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
InDex Pharmaceuticals Holding AB (publ) interim report January – June 2017
First patient enrolled in the CONDUCT study
InDex Pharmaceuticals gets new patent granted in Europe
July 6, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides additional protection for the use of cobitolimod for the treatment of inflammatory diseases.
InDex Pharmaceuticals enrolls first patient in the phase IIb study CONDUCT with cobitolimod
June 21, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical study CONDUCT – a phase IIb dose optimisation study with the drug candidate cobitolimod. Cobitolimod is a first in class immunotherapeutic, which is being developed for the treatment of moderate to severe active ulcerative colitis.
Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
May 30, 2017 – The Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) took place on Tuesday, May 30, 2017 in the company´s premises at Tomtebodavägen 23a in Stockholm, Sweden.
InDex Pharmaceuticals Holding AB (publ) interim report January – March 2017
The CONDUCT study starts. Period January – March 2017. Revenues amounted to SEK 0.0 (0.0) million. Operating result amounted to SEK –22.1 (–6.9) million. Result after tax amounted to SEK –22.0 (–7.1) million, corresponding to SEK –0.35 per share (–0.23) before and after dilution
Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
April 27, 2017 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on Tuesday, May 30, 2017 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.
InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2016
InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2016. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website.
InDex Pharmaceuticals gets patent for additional DIMS compounds granted in the US
March 14, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company’s DIMS platform has been granted by the United States Patent and Trademark Office (USPTO).
InDex Pharmaceuticals appoints new CFO
March 8, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has appointed Johan Giléus as new Chief Financial Officer (CFO) from May 1, 2017.
InDex Pharmaceuticals Holding AB (publ) year end report 2016
Focus on the final preparations of the CONDUCT study
InDex Pharmaceuticals enters agreement with CRO for the CONDUCT study
February 1, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with the global contract research organization (CRO) PAREXEL for the implementation of the CONDUCT study. CONDUCT is a phase IIb dose optimisation study with the drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis.
InDex Pharmaceuticals Holding AB (publ) interim report January – September 2016
Initial public offering and listing on Nasdaq First North Stockholm Period July – September 2016 Revenues amounted to MSEK 0.0 (0.0) Operating result amounted to MSEK -6.6 (-7.5) Result after…
InDex Pharmaceuticals gets new patent granted in the US
November 3, 2016 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be granted by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
